Goodwin Procter advised Avadel Pharmaceutics plc on the deal. Avadel Pharmaceuticals announced an underwritten public offering of 10,000,001 of its ordinary shares, nominal value $0.01 per...
Avadel Pharmaceutics’ $125 Million follow-on Equity Offering
Viatris’ $3.335 Billion Combination of Biosimilars Portfolio with Biocon Biologics
Cravath and Saraf and Partners represented Viatris in the transaction while Shardul Amarchand Mangaldas & Co and Goodwin Procter advised Biocon Biologics. Viatris Inc. reached a...